# Resource Summary Report

Generated by RRID on Sep 6, 2026

## Purified anti-human CD20 (Maxpar(R) Ready)

RRID:AB_2562816
Type: Antibody

### Proper Citation

BioLegend Cat# 302343, RRID:AB_2562816

### Antibody Information

**URL:** http://antibodyregistry.org/AB_2562816

**Proper Citation:** BioLegend Cat# 302343, RRID:AB_2562816

**Target Antigen:** CD20

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC, CyTOF®

**Antibody Name:** Purified anti-human CD20 (Maxpar(R) Ready)

**Description:** This monoclonal targets CD20

**Target Organism:** cynomolgus, rhesus, human

**Clone ID:** Clone 2H7

**Antibody ID:** AB_2562816

**Vendor:** BioLegend

**Catalog Number:** 302343

**Record Creation Time:** 20231110T035220+0000

**Record Last Update:** 20260901T034538+0000

### Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD20 (Maxpar(R) Ready).

No alerts have been found for Purified anti-human CD20 (Maxpar(R) Ready).

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Rigby RE, et al. (2026) Single-cell analysis of signalling and transcriptional responses to type I interferons. EMBO reports, 27(9), 2491.

Gerassy-Vainberg S, et al. (2024) A personalized network framework reveals predictive axis of anti-TNF response across diseases. Cell reports. Medicine, 5(1), 101300.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 185(5), 916.

Fox-Fisher I, et al. (2022) B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med (New York, N.Y.), 3(7), 468.

van Montfoort N, et al. (2018) NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell, 175(7), 1744.